Crizotinib CAS 877399-52-5 Assay ≥99.0% API Ụlọ ọrụ dị elu
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta Crizotinib (CAS: 877399-52-5) nwere oke mma.Ruifu Chemical nwere ike ịnye nnyefe zuru ụwa ọnụ, ọnụahịa asọmpi, ọrụ magburu onwe ya, obere na nnukwu ọnụọgụ dị.Ịzụta Crizotinib,Please contact: alvin@ruifuchem.com
| Aha Chemical | Crizotinib |
| Ụdị okwu | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1- (2,6-Dichloro-3-Fluoro-phenyl) -ethoxy] -5- (1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R) -3-[1- (2,6-Dichloro-3-Fluorophenyl)ethoxy] -5- (1-Piperidin-4-yl-1H- pyrazol-4-yl) pyridin-2-ylamine |
| Nọmba CAS | 877399-52-5 |
| Ọnọdụ Ahịa | Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms |
| Usoro ihe omimi | C21H22Cl2FN5O |
| Ibu molekụla | 450.34 |
| Ebe Na-agbaze | 192 ℃ |
| Njupụta | 1.47±0.10 g/cm3 |
| Okpomọkụ nchekwa | Okpomọkụ ụlọ |
| Mmalite | Shanghai, China |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
| njirimara | Site na IR, HPLC |
| Ngwọta doo anya | Dabaa na Standard |
| Ọnwụ na ihicha | ≤1.00% |
| Ihe fọdụrụ na mgbanye | ≤0.50% |
| Ihe adịghị ọcha emetụtara | (nke HPLC) |
| Otu adịghị ọcha | ≤0.50% |
| Mgbakọta adịghị ọcha | ≤1.00% |
| Ọla dị arọ | ≤20ppm |
| Nyocha | ≥99.0% |
| Ihe mgbaze fọdụrụnụ | Zute nkọwapụta ahụ |
| Ndụ shelf | Ọnwa 24 |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
ngwugwu:Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Debe akpa ahụ nke ọma ma chekwaa n'ebe dị jụụ, kpọrọ nkụ (2 ~ 8 ℃) yana ụlọ nkwakọba ihe nke ọma na-esi na ihe ndị na-adabaghị adaba.Chebe site na ìhè na mmiri mmiri.
Mbupu:Jiri ikuku na-ebuga ụwa niile site na FedEx / DHL Express.Nye nnyefe ngwa ngwa na ntụkwasị obi.
Nkọwa nchekwa 24/25 - Zere kọntaktị na akpụkpọ ahụ na anya.
NJ UN UN 3077 9 / PGIII
WGK Germany 3
Koodu HS 2933990099
Klas ihe egwu IGBO
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), bụ ike na nhọrọ ATP asọmpi obere molecule inhibitor nke ALK na c-Met.N'August 2011, United States FDA kwadoro Crizotinib maka ọgwụgwọ nke anaplastic lymphoma kinase (ALK) megharịrị ọrịa cancer akpa ume na-abụghị obere cell (NSCLC).Crizotinib bụ dual ATP asọmpi inhibitor nke tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) na ALK (cellular IC50 = 20 nM), nke abụọ bụ ihe dị mkpa ezubere maka chemotherapy cancer.Mgbe a nwalere crizotinib maka selectivity megide ndị ọzọ kinases, a chọpụtara na ọ nwere enzyme IC50's n'ime 100-fold multiples nke c-MET maka 13 nke 120 kinases nwalere.Na nyocha ekwentị, achọpụtara crizotinib ka ọ na-egbochi RON (recepteur d'origine nantais) kinase na windo selectivity ugboro iri n'elu c-MET.
Crizotinib (PF-02341066) Crizotinib bụ onye nwere ike c-Met na ALK inhibitor, ụkpụrụ IC50 dị na nyocha cell bụ 11 nM na 24 nM, n'otu n'otu.Ọ bụkwa onye na-egbochi ROS1 nwere uru Ki na-erughị 0.025 nM.Crizotinib nwere ike ibute autophagy n'ụdị ahịrị mkpụrụ ndụ kansa akpa ume site na igbochi ụzọ STAT3.
Crizotinib bụ onye na-egbochi ihe mgbochi mesenchymal-epithelial (c-MET) kinase na anaplastic lymphoma kinase (ALK).Crizotinib bụ ihe na-akpata antitumor.N'August 2011, United States FDA kwadoro crizotinib maka ọgwụgwọ nke anaplastic lymphoma kinase (ALK) megharịrị ọrịa cancer akpa ume na-abụghị obere cell (NSCLC).
Crizotinib (Xalkori (R), Pfizer), nke akwadoro na 2011, bụ onye mmechi izizi akwadoro na-elekwasị anya anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) nke tyrosine kinase insulin receptor class na MET proto-oncogene-encoded kinase nke hepatocyte growth factor receptor (HGFR) klas bụ ndị ọzọ kinases ezubere iche site crizotinib. Mgbe akwadoro na 2011, crizotinib bụ nke mbụ. ọgwụ na-ezubere iche maka ndị ọrịa NSCLC.Agbanyeghị, a na-ahụkarị iguzogide crizotinib n'ihe dị ka ọnwa 8 ka emechara ngwa mbụ yana ihe karịrị ọkara nke ndị ọrịa a na-agwọ crizotinib nwetara mmetụta ọnya afọ.Na 2016, akwadoro Crizotinib maka ROS1-positive NSCLC site na FDA.
Crizotinib (Xalkori) bụ onye na-anabata ọnụ tyrosine kinase inhibitor nke egosipụtara maka ọgwụgwọ ndị ọrịa nwere ọrịa kansa akwara na-abụghị obere cell (NSCLC) ma ọ bụ metastatic.Mmetụta ndị a na-ejikarị na Xalkori gụnyere ọrịa iku ume elu, ọgbụgbọ, vomiting, mgbu afọ, agụụ na-ebelata, ehighi ura, isi ọwụwa, ike ọgwụgwụ, afọ ọsịsa, afọ ntachi, ihe ọkụ ọkụ ma ọ bụ itching, mgbaàmà oyi (imi imi, uzere, akpịrị akpịrị), nhụjuanya ma ọ bụ tingling, ma ọ bụ ọzịza n'aka ma ọ bụ ụkwụ gị.
